3 Medicine and Diagnostic Chain Stocks With a Strong Future Roadmap: Alkem Laboratories, Medplus Health Services and Suraksha Diagnostic

Medicine and diagnostic chain stocks give investors exposure to medicines, pharmacy sales and diagnostic tests. Prescription volumes, store additions and test volumes decide how much of that demand turns into profit.

This list covers three medicine and diagnostic chain stocks: Alkem Laboratories for branded generics franchise, Medplus Health Services for pharmacy retail chain and Suraksha Diagnostic for diagnostic centre network. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Medicine and Diagnostic Chain Stocks?

Medicine and diagnostic chain stocks are shares of companies that make medicines, sell them through pharmacies and run diagnostic centres. Results depend on prescription volumes, store additions and test volumes, so margins and network growth separate the stronger names.

Medicine and Diagnostic Chain Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three medicine and diagnostic chain stocks as of the 9 Oct 2026 close.

Among healthcare supply chain stocks, all three trade at a discount to their industry P/E multiples.

Why Do Medicine and Diagnostic Chain Stocks Have a Strong Roadmap in India?

Medicine and diagnostic chain stocks have a strong roadmap in India because health spending rises with income, ageing and awareness, and each stage of care needs medicines and tests. Three drivers stand out.

• Ageing population: More chronic conditions raise demand for medicines and tests.
• Organised retail: Chains gain share from small independent shops.
• Preventive testing: More people take regular health tests.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26 and 24.57% in Q1 FY27 against 26.36% a year earlier.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.

Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap

Medplus' roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.

Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26 and 8.14% in Q1 FY27 against 9.45% a year earlier.

Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.

What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.

Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline

Suraksha Diagnostic's roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.

Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.

Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.

Best Medicine and Diagnostic Chain Stocks in India: Alkem vs Medplus vs Suraksha Diagnostic on Key Financials

Among the best medicine and diagnostic chain stocks in India, Alkem leads on return on equity and the lowest P/E; Medplus leads on Q1 FY27 revenue growth and FY26 net profit growth; Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin. The table puts the numbers side by side.

Healthcare earnings follow prescription volumes, store additions and test volumes, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Medicine and Diagnostic Chain Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen medicine and diagnostic chain stocks and shortlist medicine and diagnostic chain stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check whether margins improve as the store and centre network grows.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these medicine and diagnostic chain stocks

Risks to Consider Before Investing in Medicine and Diagnostic Chain Stocks

• Margins: Alkem's Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.
• Price controls: Government limits on drug prices can reduce margins.
• Competition: Online platforms and large chains compete for the same customers.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Alkem, Medplus and Suraksha Diagnostic live.

Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.

Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.

The shareholding pattern published every quarter shows whether promoters, mutual funds and foreign investors are raising or trimming their holdings, which adds useful context to the financial numbers.

Spreading money across several sectors and company sizes helps keep a portfolio steady, because each business responds differently to interest rates, commodity prices and consumer demand.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare supply chain stocks cover branded medicines, pharmacy retail and diagnostic centres. Alkem leads on return on equity and the lowest P/E; Medplus leads on Q1 FY27 revenue growth and FY26 net profit growth; Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin.

Across medicine and diagnostic chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the medicine and diagnostic chain stocks to buy discussed here.

FAQs on Medicine and Diagnostic Chain Stocks

Which are the best medicine and diagnostic chain stocks in India with a strong roadmap?

Ans. Alkem Laboratories, Medplus Health Services and Suraksha Diagnostic stand out for their roadmaps in branded medicines, pharmacy retail and diagnostic centres. FY26 revenue growth was 13.7% at Alkem, 12.6% at Medplus and 22.5% at Suraksha Diagnostic, and return on equity ranges from 11.12% to 16.66%.

Is Alkem Laboratories a good stock to buy now?

Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, price controls and competition move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Alkem, Medplus and Suraksha Diagnostic?

Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 36.06 for Medplus (industry 66.59) and 46.05 for Suraksha Diagnostic (industry 62.79). All of them trade below the industry multiple.

Which of these medicine and diagnostic chain stocks has the highest return on equity?

Ans. Alkem Laboratories has the highest return on equity at 16.66%, followed by Suraksha Diagnostic at 13.15% and Medplus Health Services at 11.12%.

What are the risks of investing in medicine and diagnostic chain stocks?

Ans. The main risks are margins, price controls, competition and quarterly trends. Alkem's Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.

How did Alkem, Medplus and Suraksha Diagnostic perform in Q1 FY27?

Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year.

Do medicine and diagnostic chain stocks pay dividends?

Ans. Alkem and Suraksha Diagnostic pay dividends. The dividend yield is 1.01% for Alkem and 0.02% for Suraksha Diagnostic, based on dividends declared for FY26.

How can I invest in medicine and diagnostic chain stocks in India?

Ans. You can buy medicine and diagnostic chain stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.